Claudin18.2 CAR-T cells
PreclinicalCell therapy
Claudin18.2 CAR-T cells is one of 22 biologic programs targeting Advanced Malignant Solid Tumors. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
21
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
35 competitors in Advanced Malignant Solid Tumors
#DrugCompanyPhaseTrials
1Opdivo
Bristol-Myers SquibbPhase 2
Gemzar
Johnson & JohnsonPhase 2
Eloxatin
TevaPhase 2
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 2
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 2
Tuoyi
CCoherus Oncology, Inc.
Phase 2
JS207
SShanghai Junshi Bioscience Co., Ltd.
Phase 2
Chemotherapy Drug
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 2
QL1706
Qilu Pharmaceutical Co., Ltd.Phase 2
QLS31905
Qilu Pharmaceutical Co., Ltd.Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Claudin18.2 CAR-T cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details